0000950170-24-078748.txt : 20240627 0000950170-24-078748.hdr.sgml : 20240627 20240627214117 ACCESSION NUMBER: 0000950170-24-078748 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240625 FILED AS OF DATE: 20240627 DATE AS OF CHANGE: 20240627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRIEDMAN PAUL A CENTRAL INDEX KEY: 0001236927 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 241081126 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION STREET 2: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 4 1 ownership.xml 4 X0508 4 2024-06-25 0001157601 MADRIGAL PHARMACEUTICALS, INC. MDGL 0001236927 FRIEDMAN PAUL A C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false false false false Common Stock 2024-06-25 4 A false 714 0.00 A 186449 D Common Stock 655540 I By SQN LLC Stock Option (Right to Buy) 280.04 2024-06-25 4 A false 1105 0 A 2031-06-25 Common Stock 1105 1105 D Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date. The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. /s/ Mardi Dier, as Attorney-in-Fact 2024-06-27